AKT1 and breast carcinoma: Interestingly, in basal-like and mesenchymal breast cancers the PI3K-AKT and MEK-ERK pathways are often activated, resulting in high levels of JUN and FOSL1, whereas luminal A breast cancers do not show activation of the ERK1/2 MAP-kinase pathway [44–47].